查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球减重疗法市场 - 2023-2030年
市场调查报告书
商品编码
1290361

全球减重疗法市场 - 2023-2030年

Global Weight Loss Therapeutics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

2022年，全球减重治疗市场达到27.98亿美元，预计到2030年将出现有利可图的增长，达到149.771亿美元。在预测期内（2023-2030年），全球减肥治疗剂市场预计将呈现24.3%的复合年增长率。

减肥疗法市场范围包括已获批准的药物，如Liraglutide（Saxenda）、Naltrexone-Bupropion（Contrave）、Phentermine-Topiramate（Qsymia）、Semaglutide（Wegovy）和Orlistat（Xenical，Alli）及其他，这增加了减肥疗法的市场份额。

心血管疾病的发病率越来越高，新型药物的研发越来越多，推动了减肥治疗剂市场的需求趋势。全球减肥治疗剂市场正在扩大，因为包括治疗剂的不断进步和它们在各国即将获得的医疗批准等因素也为减肥治疗剂市场的增长创造了一个积极的前景。

市场动态

慢性疾病发病率的增加推动了减重疗法市场的增长。

因为它与精神健康状况不佳和生活质量下降有关，肥胖是一个严重的健康问题。此外，在美国和世界各地，它与各种类型的癌症、心脏病、糖尿病和其他主要杀手有联系。一个人如果超重，就更容易有高胆固醇和高血压。这两种疾病会增加患心脏病或中风的风险。

患心脏病或中风的可能性可以通过减少少量的体重而降低。十个患有2型糖尿病的人中有八个是肥胖或超重的。最终，高血糖导致其他健康问题，如神经损伤、视力问题、肾脏疾病、心脏病和中风。因此，越来越多的慢性疾病正在推动减肥治疗剂市场的发展。

饮食习惯和生活方式的改变为制造商创造了有利可图的机会

由于技术的进步和全球环境变化带来的生活方式的改变，减肥疗法的市场机会越来越大。推动减肥疗法市场的另一个因素是成人中许多疾病的发病率不断上升，如糖尿病和肥胖症。澳大利亚肥胖症和超重率的上升是全球趋势的结果。

今天，高达75%的男性，超过50%的女性，以及约25%的儿童和青少年被认为是超重或肥胖的。环境和不断变化的生活方式无疑有很大的影响，现在高能量的饭菜可以广泛获得，而且不再需要体育活动。因此，肥胖及其引起的健康问题在澳大利亚人中不幸变得非常频繁。

减肥药相关的副作用将阻碍市场的增长

为了达到最佳效果，减重药物要与低热量饮食和经医生批准的运动计划一起使用。然而，除非继续进行饮食和运动，否则人们在停止使用减重药物后，可能会重新获得部分减掉的体重。

一些病人发现强化行为治疗不足以帮助他们减肥。他们还纠结于与他们的体重有关的其他问题。这些可能包括荷尔蒙问题或有遗传根源的体重问题。因此，上述这些因素限制了减肥治疗剂市场的增长。

COVID-19影响分析

由于COVID-19大流行和世界上许多国家的封锁，所有行业的公司的财务健康都受到影响。因此，在COVID-19公共卫生紧急情况期间，美国食品和药物管理局（FDA）发布了指导方针，其中包括帮助赞助商和研究人员的一般注意事项，确保试验参与者的安全，坚持良好的临床实践（GCP），并尽量减少试验完整性的风险。

俄乌战争影响分析

俄罗斯-乌克兰冲突估计对全球减重疗法市场的影响不大，因为该地区的主要市场参与者数量不多。然而，在预测期内，原材料进出口的影响预计对全球减重治疗剂市场的增长影响不大。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按已批准的药物进行分析
  • 按分销渠道分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 主要公司的临床试验不断增加
      • 慢性疾病发病率的增加
    • 限制因素
      • 减肥药物的相关副作用
    • 机会
      • 饮食习惯和生活方式的改变
    • 影响分析

第五章：行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按批准药物分类

  • 利拉鲁肽(Saxenda)
  • 纳曲酮-安非他酮（Contrave）
  • 芬特明-托吡酯(Qsymia)
  • 塞马鲁肽（维格威）
  • 奥利司他(Xenical, Alli)
  • Setmelanotide (Imcivree)

第8章：按分销渠道

  • 医院药房
  • 零售药店
  • 网上药店

第九章：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
      • 亚太其他地区
  • 中东和非洲
    • 关键区域的动态

第十章：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十一章 ：公司简介

  • Novo Nordisk A/S
    • 公司概述
    • 产品组合和说明
    • 财务概况
    • 主要发展情况
  • Currax Pharmaceuticals LLC
  • Viking Therapeutics
  • Pfizer Inc.
  • Eli Lilly and Company
  • Altimmune
  • VIVUS LLC
  • Rhythm Pharmaceuticals
  • Amgen Inc.
  • Zealand Pharma A/S

第十二章 ：附录

简介目录
Product Code: PH3616

Market Overview

The Global Weight Loss Therapeutics Market reached US$ 2,798.0 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 14,978.1 million by 2030. The global weight loss therapeutics market is expected to exhibit a CAGR of 24.3% during the forecast period (2023-2030).

The weight loss therapeutics market scope comprises approved drugs such as Liraglutide (Saxenda), Naltrexone-Bupropion (Contrave), Phentermine-Topiramate (Qsymia), Semaglutide (Wegovy) and Orlistat (Xenical, Alli) and others, which has increased the weight loss therapeutics market share.

The increasing prevalence of cardiovascular disorders and the growing research and development for novel drugs are driving up demand for weight loss therapeutics market trends. The global market for weight loss therapeutics is expanding as a result of factors including the increasing advances in therapeutics and their upcoming medical approvals across countries are also creating a positive outlook for the weight loss therapeutics market growth.

Market Dynamics

An Increase in the Incidence of Chronic Disorders Drives the Growth of the Weight Loss Therapeutics Market.

Because it is linked to poor mental wellness outcomes and a decreased quality of life, obesity is a severe health problem. Additionally, it has links to various types of cancer, heart disease, diabetes, and other major killers in the US and around the world. One is more prone to have high cholesterol and blood pressure if they are overweight. These two disorders increase the risk of developing heart disease or stroke.

The likelihood of having heart disease or a stroke can be decreased by losing a small amount of weight. Eight out of ten individuals with type 2 diabetes are obese or overweight. Eventually, high blood sugar causes other health issues such as nerve damage, vision problems, renal disease, heart disease, and stroke. Hence, the growing number of chronic disorders is driving the weight loss therapeutics market.

The Change in Food Habits and Lifestyle Creates Lucrative Opportunities for Manufacturers

Due to advancing technologies and changes in lifestyle brought on by a changing global environment, there is a growing market opportunity for weight loss therapies. Another factor driving the weight loss treatments market is the increasing prevalence of numerous illnesses among adults, such as diabetes and obesity. The rising rates of obesity and overweight in Australia are a result of a global trend.

Today, up to 75% of men, over 50% of women, and about 25% of kids and teenagers are considered overweight or obese. The environment and evolving lifestyles undoubtedly have a big impact now that high-energy meals are widely accessible and physical activity is no longer required. As an outcome, obesity and the health issues it causes have unfortunately become all too frequent in Australians.

Side Effects Associated with Weightloss Drugs Will Hamper the Growth of the Market

For optimal results, weight reduction drugs are used with a low-calorie diet and an exercise program that has been approved by a doctor. However, unless diet and exercise are continued, people may gain back part of the weight they lost after they stop using weight reduction medications.

Some patients find that intensive behavioral therapy is insufficient to help them lose weight. They also struggle with additional concerns that are related to their weight. These can include hormonal issues or weight issue that has genetic roots. Hence these above mentioned factors are limiting the weight loss therapeutics market's growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global weight loss therapeutics market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global weight loss therapeutics market growth over the forecast period.

Segment Analysis

The global weight loss therapeutics market is segmented based on approved drugs, distribution channel and region.

Liraglutide (Saxenda) from the Approved Drugs Segment Accounts for Approximately 32.3% of the Market Share

Liraglutide is beneficial in causing and maintaining weight loss in a population of obese people, including those with type 2 diabetes, hypertension, dyslipidemia, and obstructive sleep apnea. Liraglutide is a prescription anti-diabetic drug used for the treatment of obesity, type 2 diabetes, and persistent weight management. It is marketed under the brand name Victoza among others.

The U.S. FDA has approved an additional indication for Saxenda (liraglutide) in juvenile patients aged 12 and older who are obese, as determined by a specified body mass index (BMI), for the purpose of managing chronic weight. Saxenda is an adjuvant (extra therapy) to a low-calorie diet and increased physical exercise. Liraglutide helps patients with obesity lose weight and keep it off. Improved glycemic control is a special benefit provided by the medication.

Geographical Analysis

North America Accounted for Approximately 42.3% of the Market Share Owing to the Strong Presence of Major Players And Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for weight loss therapeutics for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised the industrial production of weight loss therapeutics, which has increased the demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand for weight loss therapeutics.

Rising new product types or applications will drive market growth. Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of diagnostic approaches for cancer or various other disorders, leading to the expansion of the market in this region. These factors show the dominance of North America.

Competitive Landscape

The major global players in the weight loss therapeutics market include: F Hoffmann-la Roche Ltd, Currax Pharmaceuticals LLC, Viking Therapeutics, Pfizer Inc., Eli Lilly and Company, Altimmune, VIVUS LLC, Rhythm Pharmaceuticals, Amgen Inc. and Zealand Pharma A/S among others.

Why Purchase the Report?

  • To visualize the global weight loss therapeutics market segmentation based on approved drugs, distribution channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of weight loss therapeutics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global weight loss therapeutics market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Approved Drugs
  • 3.2. Snippet by Distribution Channel
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Rising Clinical Trials by Key Companies
      • 4.1.1.2. An Increase in the Incidence of Cronic Disorders
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with Weighloss Drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. The Change in Food Habits and Lifestyle
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Approved Drugs

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 7.1.2. Market Attractiveness Index, By Approved Drugs
  • 7.2. Liraglutide (Saxenda) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Naltrexone-bupropion (Contrave)
  • 7.4. Phentermine-topiramate (Qsymia)
  • 7.5. Semaglutide (Wegovy)
  • 7.6. Orlistat (Xenical, Alli)
  • 7.7. Setmelanotide (Imcivree)

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacies *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan

Australia

      • 9.5.5.4. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Novo Nordisk A/S *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Currax Pharmaceuticals LLC
  • 11.3. Viking Therapeutics
  • 11.4. Pfizer Inc.
  • 11.5. Eli Lilly and Company
  • 11.6. Altimmune
  • 11.7. VIVUS LLC
  • 11.8. Rhythm Pharmaceuticals
  • 11.9. Amgen Inc.
  • 11.10. Zealand Pharma A/S

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us